摘要
目的探讨PTP1B在上皮性卵巢癌中的表达及与临床病理特征和预后的关系。方法应用Oncomine数据库和免疫组化法检测卵巢癌组织中PTP1B的表达情况,进一步分析PTP1B表达与卵巢癌临床病理特征及预后的关系。结果通过Oncomine数据库分析发现PTP1B在卵巢浆液性囊腺癌组织中的表达高于正常组织(P <0. 001)。免疫组化结果显示PTP1B表达与卵巢癌FIGO分期(P <0. 001)和大网膜转移相关(P=0. 002)。Kaplan-Meier生存分析显示,与PTP1B低表达组相比,PTP1B高表达组患者的总生存期更短(P <0. 001)。多因素分析显示FIGO分期和PTP1B表达是影响卵巢癌患者总生存期的独立预后因素。结论卵巢癌中PTP1B表达与肿瘤进展和患者不良预后密切相关。PTP1B可能是影响卵巢癌患者不良预后的有价值评估指标之一。
Purpose To investigate the expressions of PTP1B in epithelial ovarian cancer tissues and to analysis its correlation with clinical pathological and survival significance.Methods The expression of PTP1B in ovarian cancer tissues was detected by Oncomine database and immunohistochemistry.The relationships between PTP1B expression and clinicopathological features,including prognosis significance,were analyzed.Results Oncomine database showed that the mRNA expression of PTP1B in ovarian cancer was significantly higher than that in normal tissues(P<0.001).Immunohistochemical staining showed that PTP1B expression was significantly correlation with FIGO stage(P<0.001),omentum majus metastasis(P=0.002).Kaplan-Meier analyses revealed that ovarian cancer patients with high PTP1B expression tumors had a significantly worse overall survival rate than those with low PTP1B expression tumors(P<0.001).Multivariate analysis showed that FIGO stage,PTP1B expression were independent survival predictors.Conclusion PTP1B expression may be involved in the tumor progression and poor prognosis of patients with ovarian cancer,and it might be used as one of the valuable markers for poor prognosis in patients with ovarian cancer.
作者
彭青群
徐智燕
甘跃敏
赵瑞君
PENG Qing-qun;XU Zhi-yan;GAN Yue-min;ZHAO Rui-jun(Department of Gynaecology and Obstetrics,Leping Maternal and Child Health Care Hospital,Leping 333300,China;Prevention and Cure Center of Breast Disease,the Third Hospital of Nanchang,Nanchang 330009,China)
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2019年第3期282-285,共4页
Chinese Journal of Clinical and Experimental Pathology
